Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 4;12(8):1015.
doi: 10.3390/pathogens12081015.

Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa

Affiliations
Review

Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa

Afsatou Ndama Traoré et al. Pathogens. .

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), remains a significant global health issue, with high morbidity and mortality rates. The emergence of drug-resistant strains, particularly multidrug-resistant TB (MDR-TB), poses difficult challenges to TB control efforts. This comprehensive review and meta-analysis investigated the prevalence of and molecular insights into isoniazid (INH) and rifampicin (RIF) resistance-conferring mutations in M. tb isolates from South Africa. Through systematic search and analysis of 11 relevant studies, we determined the prevalence of gene mutations associated with RIF and INH resistance, such as rpoB, katG, and inhA. The findings demonstrated a high prevalence of specific mutations, including S450L in rpoB, and S315T, which are linked to resistance against RIF and INH, respectively. These results contribute to the understanding of drug resistance mechanisms and provide valuable insights for the development of targeted interventions against drug-resistant TB.

Keywords: INH; RIF; drug resistance mechanisms; resistance-conferring mutations; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the literature search strategy, search results, and inclusion and exclusion of articles.
Figure 2
Figure 2
Forest plot showing heterogeneity among studies investigating gene mutations in SA [4,5,7,8,9,10,11,12,13,14,15].

Similar articles

Cited by

References

    1. World Health Organization (WHO) Global Tuberculosis Report 2020. WHO; Geneva, Switzerland: 2020. [(accessed on 16 April 2021)]. Available online: https://www.who.int/publications/i/item/9789240013131.
    1. World Health Organization (WHO) Global Tuberculosis Report 2019. WHO; Geneva, Switzerland: 2019. [(accessed on 16 April 2021)]. Available online: https://www.who.int/publications/i/item/9789241565714.
    1. Abebe G., Paasch F., Apers L., Rigouts L., Colebunders R. Tuberculosis drug resistance testing by molecular methods: Opportunities and challenges in resource-limited settings. J. Microbiol. Methods. 2022;84:155–160. doi: 10.1016/j.mimet.2010.11.014. - DOI - PubMed
    1. Cox H., Goig G.A., Salaam-Dreyer Z., Dippenaar A., Reuter A., Mohr-Holland E., Daniels J., Cudahy P.G., Nicol M.P., Borrell S., et al. Whole-genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high-burden settings: A retrospective cohort study. J. Clin. Microbiol. 2022;60:e0236221. doi: 10.1128/jcm.02362-21. - DOI - PMC - PubMed
    1. Oostvogels S., Ley S.D., Heupink T.H., Dippenaar A., Streicher E.M., De Vos E., Meehan C.J., Dheda K., Warren R., Van Rie A. Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa. Microb. Genom. 2022;8:000815. doi: 10.1099/mgen.0.000815. - DOI - PMC - PubMed

LinkOut - more resources